http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022104754-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-162
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4839
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-7275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-6898
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H40-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-1124
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H40-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
filingDate 2021-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8a0938a5af8b5896d14932812d5274d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b72580d821ac72d962d97e233ea1b7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab5f864d554108ee23e786c69b3332a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1823a3357708a47d5915eaafd3028f47
publicationDate 2022-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2022104754-A1
titleOfInvention Digital biomarker
abstract Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the axial motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.
priorityDate 2019-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100171813
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID396689
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID118513932
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID30432
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424688741
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID69305
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6606
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2541340
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID266605
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID856609
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID102130507
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2542002
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433108945
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID64301
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281492
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID20595
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135565042
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID28960

Total number of triples: 44.